Vuzix Corp - Quarter Report: 2023 March (Form 10-Q)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the Quarterly Period Ended March 31, 2023
OR
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission file number 001-35955
(Exact name of registrant as specified in its charter)
Delaware |
| 04-3392453 |
State or other jurisdiction of | (I.R.S. Employer |
25 Hendrix Road, Suite A |
| 14586 |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (585) 359-5900
Securities registered pursuant to Section 12(b) of the Act:
Title of each class: |
| Trading Symbol(s) |
| Name of each exchange on which registered: |
Common Stock, par value $0.001 |
| VUZI |
| Nasdaq Capital Market |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | Non-accelerated filer | ☒ |
|
|
|
|
|
|
Smaller reporting company | ☒ | Emerging growth company | ☐ |
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of May 10, 2023, there were 63,219,123 shares of the registrant’s common stock outstanding.
Vuzix Corporation
INDEX
2
Part 1: FINANCIAL INFORMATION
Item 1: Consolidated Financial Statements
VUZIX CORPORATION
CONSOLIDATED BALANCE SHEETS
(Unaudited) |
| |||||
March 31, | December 31, | |||||
| 2023 |
| 2022 | |||
ASSETS |
|
|
|
| ||
Current Assets |
|
|
|
| ||
Cash and Cash Equivalents | $ | 63,235,863 | $ | 72,563,943 | ||
Accounts Receivable, Net |
| 3,059,156 |
| 3,558,971 | ||
Accrued Revenues in Excess of Billings |
| 192,177 |
| 269,129 | ||
Employee Retention Credit Receivable | 466,705 | 466,705 | ||||
Inventories, Net |
| 10,861,679 |
| 11,267,969 | ||
Manufacturing Vendor Prepayments |
| 474,035 |
| 998,671 | ||
Prepaid Expenses and Other Assets |
| 1,621,186 |
| 2,115,853 | ||
Total Current Assets |
| 79,910,801 |
| 91,241,241 | ||
Long-Term Assets |
|
|
|
| ||
Fixed Assets, Net |
| 6,139,939 |
| 3,878,505 | ||
Operating Lease Right-of-Use Asset | 791,604 | 956,165 | ||||
Patents and Trademarks, Net |
| 2,341,024 |
| 2,220,094 | ||
Technology Licenses, Net |
| 29,331,805 |
| 30,158,689 | ||
Intangible Asset, Net |
| 640,383 |
| 675,313 | ||
Goodwill |
| 1,601,400 |
| 1,601,400 | ||
Other Assets, Net |
| 1,715,996 |
| 1,581,143 | ||
Total Assets | $ | 122,472,952 | $ | 132,312,550 | ||
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
| |||
Current Liabilities |
|
|
|
| ||
Accounts Payable | $ | 1,271,365 | $ | 1,211,747 | ||
Unearned Revenue |
| 41,454 |
| 29,064 | ||
Accrued Expenses |
| 1,466,214 |
| 1,670,539 | ||
Licensing Fees Commitment |
| 9,500,000 |
| 11,500,000 | ||
Income and Other Taxes Payable |
| 22,841 |
| 214,997 | ||
Operating Lease Right-of-Use Liability | 562,375 | 651,011 | ||||
Total Current Liabilities |
| 12,864,249 |
| 15,277,358 | ||
Long-Term Liabilities | ||||||
Operating Lease Right-of-Use Liability | 229,229 | 305,154 | ||||
Total Liabilities |
| 13,093,478 |
| 15,582,512 | ||
Stockholders' Equity |
|
|
|
| ||
Common Stock - $0.001 Par Value, 100,000,000 shares authorized; 63,787,858 shares issued and 63,208,186 shares outstanding as of March 31, 2023 and 63,783,779 shares issued and 63,319,107 shares outstanding as of December 31, 2022. |
| 63,787 |
| 63,783 | ||
Additional Paid-in Capital |
| 365,868,487 |
| 362,507,715 | ||
Accumulated Deficit |
| (254,076,299) |
| (243,835,716) | ||
Treasury Stock, at cost, 579,672 shares as of March 31, 2023 and 464,672 shares as of December 31, 2022. |
| (2,476,501) |
| (2,005,744) | ||
Total Stockholders' Equity |
| 109,379,474 |
| 116,730,038 | ||
Total Liabilities and Stockholders' Equity | $ | 122,472,952 | $ | 132,312,550 |
The accompanying notes are an integral part of these consolidated financial statements.
3
VUZIX CORPORATION
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(Unaudited)
Common Stock | Additional | Accumulated | Treasury Stock | ||||||||||||||||
| Shares |
| Amount |
| Paid-In Capital |
| Deficit |
| Shares |
| Amount |
| Total | ||||||
Balance - January 1, 2023 |
| 63,783,779 | $ | 63,783 | $ | 362,507,715 | $ | (243,835,716) | (464,672) | $ | (2,005,744) | $ | 116,730,038 | ||||||
Stock-Based Compensation Expense |
| — |
| — |
| 3,360,772 |
| — |
| — |
| — |
| 3,360,772 | |||||
Stock Option Exercises |
| 4,079 |
| 4 |
| — |
| — |
| — |
| — |
| 4 | |||||
Purchases of Treasury Stock |
| — |
| — |
| — |
| — |
| (115,000) |
| (470,757) |
| (470,757) | |||||
Net Loss |
| — |
| — |
| — |
| (10,240,583) |
| — |
| — |
| (10,240,583) | |||||
Balance - March 31, 2023 |
| 63,787,858 | $ | 63,787 | $ | 365,868,487 | $ | (254,076,299) |
| (579,672) | $ | (2,476,501) | $ | 109,379,474 |
Common Stock | Additional | Accumulated | Treasury Stock | ||||||||||||||||
| Shares |
| Amount |
| Paid-In Capital |
| Deficit |
| Shares |
| Amount |
| Total | ||||||
Balance - January 1, 2022 |
| 63,672,268 | $ | 63,672 | $ | 346,736,397 | $ | (203,072,143) | — | $ | — | $ | 143,727,926 | ||||||
Stock-Based Compensation Expense |
| — |
| — |
| 3,955,738 |
| — |
| — |
| — |
| 3,955,738 | |||||
Stock Option Exercises |
| 32,358 |
| 33 |
| 29,191 |
| — |
| — |
| — |
| 29,224 | |||||
Purchases of Treasury Stock |
| — |
| — |
| — |
| — |
| (36,685) |
| (251,057) |
| (251,057) | |||||
Net Loss |
| — |
| — |
| — |
| (10,506,001) |
| — |
| — |
| (10,506,001) | |||||
Balance - March 31, 2022 |
| 63,704,626 | $ | 63,705 | $ | 350,721,326 | $ | (213,578,144) |
| (36,685) | $ | (251,057) | $ | 136,955,830 |
The accompanying notes are an integral part of these consolidated financial statements.
4
VUZIX CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended March 31, | |||||||
| 2023 |
| 2022 |
| |||
Sales: |
|
|
|
|
| ||
Sales of Products | $ | 4,191,361 | $ | 2,503,051 | |||
Cost of Sales: |
|
|
|
| |||
Cost of Sales - Products Sold |
| 3,082,439 |
| 1,803,598 | |||
Cost of Sales - Depreciation and Amortization | 232,916 | 223,785 | |||||
Total Cost of Sales |
| 3,315,355 |
| 2,027,383 | |||
Gross Profit |
| 876,006 |
| 475,668 | |||
Operating Expenses: |
|
|
|
| |||
Research and Development |
| 3,069,797 |
| 3,103,444 | |||
Selling and Marketing |
| 2,539,659 |
| 2,023,435 | |||
General and Administrative |
| 5,131,824 |
| 5,453,833 | |||
Depreciation and Amortization |
| 964,265 |
| 259,245 | |||
Impairment of Patents and Trademarks |
| 17,666 |
| 49,603 | |||
Total Operating Expenses |
| 11,723,211 |
| 10,889,560 | |||
Loss From Operations |
| (10,847,205) |
| (10,413,892) | |||
Other Income (Expense): |
|
|
|
| |||
Investment Income |
| 695,783 |
| 6,280 | |||
Income and Other Taxes |
| (87,795) |
| (47,632) | |||
Foreign Exchange Loss |
| (1,366) |
| (50,757) | |||
Total Other Income (Expense), Net |
| 606,622 |
| (92,109) | |||
Loss Before Provision for Income Taxes |
| (10,240,583) |
| (10,506,001) | |||
Provision for Income Taxes |
| — |
| — | |||
Net Loss |
| (10,240,583) |
| (10,506,001) | |||
Basic and Diluted Loss per Common Share | $ | (0.16) | $ | (0.16) | |||
Weighted-average Shares Outstanding - Basic and Diluted |
| 63,216,598 |
| 63,695,127 |
The accompanying notes are an integral part of these consolidated financial statements.
5
VUZIX CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Three Months Ended March 31, | ||||||
| 2023 |
| 2022 | |||
Cash Flows from Operating Activities |
|
|
|
| ||
Net Loss | $ | (10,240,583) | $ | (10,506,001) | ||
Non-Cash Adjustments |
|
|
|
| ||
Depreciation and Amortization |
| 1,197,181 |
| 483,030 | ||
Stock-Based Compensation |
| 3,667,509 |
| 4,319,748 | ||
Impairment of Patents and Trademarks |
| 17,666 |
| 49,603 | ||
(Increase) Decrease in Operating Assets |
|
|
|
| ||
Accounts Receivable |
| 499,815 |
| 690,775 | ||
Accrued Revenues in Excess of Billings |
| 76,952 |
| — | ||
Inventories |
| 406,290 |
| (407,084) | ||
Manufacturing Vendor Prepayments |
| 524,636 |
| (82,513) | ||
Prepaid Expenses and Other Assets |
| 218,520 |
| 213,394 | ||
Increase (Decrease) in Operating Liabilities |
|
|
|
| ||
Accounts Payable |
| 59,618 |
| (831,021) | ||
Accrued Expenses |
| (412,566) |
| (292,286) | ||
Unearned Revenue |
| 12,391 |
| 1,825 | ||
Income and Other Taxes Payable |
| (192,156) |
| (74,549) | ||
Net Cash Flows Used in Operating Activities |
| (4,164,727) |
| (6,435,079) | ||
Cash Flows from Investing Activities |
|
|
|
| ||
Purchases of Fixed Assets |
| (2,284,968) |
| (57,758) | ||
Investments in Patents and Trademarks |
| (182,628) |
| (34,469) | ||
Investments in Licenses, Intangibles and Other Assets |
| (2,000,000) |
| (125,000) | ||
Investments in Software Development | (125,000) | — | ||||
Investments in Other Assets |
| (100,000) |
| — | ||
Net Cash Flows Used in Investing Activities |
| (4,692,596) |
| (217,227) | ||
Cash Flows from Financing Activities |
|
|
|
| ||
Proceeds from Exercise of Warrants |
| — |
| 29,224 | ||
Purchases of Treasury Stock | (470,757) | (251,057) | ||||
Net Cash Flows Used in Financing Activities |
| (470,757) |
| (221,833) | ||
Net Decrease in Cash and Cash Equivalents |
| (9,328,080) |
| (6,874,139) | ||
Cash and Cash Equivalents - Beginning of Period |
| 72,563,943 |
| 120,203,873 | ||
Cash and Cash Equivalents - End of Period | $ | 63,235,863 | $ | 113,329,734 | ||
Supplemental Disclosures |
|
|
|
| ||
Unamortized Common Stock Expense included in Prepaid Expenses and Other Assets | $ | 1,061,885 | $ | 1,001,232 | ||
Non-Cash Investment in Licenses | 9,500,000 | — | ||||
Stock-Based Compensation Expense - Expensed less Previously Issued | 306,737 | 364,010 |
The accompanying notes are an integral part of these consolidated financial statements.
6
VUZIX CORPORATION
NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
Note 1 – Basis of Presentation
The accompanying unaudited consolidated financial statements of Vuzix Corporation (“the Company” or “Vuzix”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the Securities and Exchange Commission (the “SEC”). Accordingly, the unaudited consolidated financial statements do not include all information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Certain re-classifications have been made to prior comparable periods to conform with current reporting impacting Costs of Sales, Gross Profit and Depreciation and Amortization. The results of the Company’s operations for the three months ended March 31, 2023 are not necessarily indicative of the results of the Company’s operations for the full fiscal year or any other period.
The accompanying interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto of the Company as of and for the year ended December 31, 2022, as reported in the Company’s Annual Report on Form 10-K filed with the SEC on March 1, 2023.
Reclassification of Prior Year Presentation
Certain prior year amounts have been reclassified for consistency with the current year’s presentation. These reclassifications had no effect on the reported results of operations. An adjustment has been made to the Consolidated Statements of Operations for the three months ended March 31, 2022, to reclassify depreciation expense related to our manufacturing operations from the amounts of reported depreciation and amortization expenses originally included in Operating Expenses. This change in classification does not affect previously reported Net Loss or reported Cash Flows Used in Operating Activities in the Consolidated Statements of Cash Flows or Consolidated Balance Sheets. The below table is a summary of the impact of these reclassifications:
| |||||||||||
| For the Three Months Ended March 31, 2022 |
| |||||||||
Condensed Statement of Operations | As Previously Presented | Reclassification | Revised | ||||||||
Total Sales | $ | 2,503,051 | $ | — | $ | 2,503,051 | |||||
Cost of Sales - Products Sold | 1,863,697 | (60,099) | 1,803,598 | ||||||||
Cost of Sales - Depreciation and Amortization | — | 223,785 | 223,785 | ||||||||
Gross Profit | 639,354 | 163,686 | 475,668 | ||||||||
Operating Expenses: | |||||||||||
Research and Development | 3,103,444 | 3,103,444 | |||||||||
Selling and Marketing | 2,023,435 | 2,023,435 | |||||||||
General and Administrative | 5,453,833 | 5,453,833 | |||||||||
Depreciation and Amortization | 422,931 | (163,686) | 259,245 | ||||||||
Impairment of Patents and Trademarks | 49,603 | 49,603 | |||||||||
Total Operating Expenses | 11,053,246 | (163,686) | 10,889,560 | ||||||||
Loss From Operations |
| (10,413,892) |
| — |
| (10,413,892) | |||||
Total Other Expense, Net | (92,109) | (92,109) | |||||||||
Net Loss | $ | (10,506,001) | $ | — | $ | (10,506,001) |
Customer Concentrations
For the three months ended March 31, 2023, one customer represented 74% of total product revenue. For the three months ended March 31, 2022, one customer represented 11% of total product revenue.
7
As of March 31, 2023, one customer represented 50% of accounts receivable. As of December 31, 2022, one customer represented 26% of accounts receivable.
Treasury Stock
Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains and losses on the subsequent re-issuance of shares will be credited or charged to paid-in capital in excess of par value using the average-cost method.
Recent Accounting Pronouncements
In June 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326). ASU 2016-13 provides for a new impairment model which requires measurement and recognition of expected credit losses for most financial assets and certain other instruments, including but not limited to, accounts receivable. The Company adopted ASU 2016-13 effective on January 1, 2023. The adoption of this standard did not have a material impact on our consolidated financial statements.
Note 2 – Revenue Recognition and Contracts with Customers
Disaggregated Revenue
The Company’s total revenue was comprised of two major product lines: Smart Glasses Sales and Engineering Services. There were no Engineering Services revenue recorded in the three months ended March 31, 2023. The following table summarizes the revenue recognized by major product line:
Three Months Ended | ||||||
March 31, | ||||||
| 2023 |
| 2022 | |||
Revenues |
|
|
|
| ||
Products Sales | $ | 4,191,361 | $ | 2,503,051 | ||
Significant Judgments
Under Topic 606 “Revenue from Contracts with Customers”, we use judgments that could potentially impact both the timing of our satisfaction of performance obligations and our determination of transaction prices used in determining revenue recognized by major product line. Such judgments include considerations in determining our transaction prices and when our performance obligations are satisfied for our standard product sales that include an end-user 30-day right to return if not satisfied with product and general payment terms that are between Net 30 and 60 days. For our engineering services, performance obligations are recognized over time using the input method and the estimated costs to complete each project are considered significant judgments.
Performance Obligations
Revenues from our performance obligations are typically satisfied at a point-in-time for Smart Glasses, Waveguides and Display Engines, and our OEM Products, which are recognized when the customer obtains control and ownership, which is generally upon shipment. The Company considers shipping and handling activities performed to be fulfillment activities and not a separate performance obligation. The Company also records revenue for performance obligations relating to our engineering services over time by using the input method measuring progress toward satisfying the performance obligations. Satisfaction of our performance obligations related to our engineering services is measured by the Company’s costs incurred as a percentage of total expected costs to project completion as the inputs of actual costs incurred by the Company are directly correlated with progress toward completing the contract. As such, the Company believes that our methodologies for recognizing revenue over time for our engineering services correlate directly with the transfer of control of the underlying assets to our customers.
8
Our standard product sales include a
( ) month assurance-type product warranty. In the case of certain of our OEM products and waveguide sales, some include a standard product warranty of up to ( ) months to allow distribution channels to offer the end customer a full ( ) months of coverage. We offer extended warranties to customers, which extend the standard product warranty on product sales for an additional ( ) month period. All revenue related to extended product warranty sales is deferred and recognized over the extended warranty period. Our engineering services contracts vary from contract to contract but typically include payment terms of Net 30 days from the date of billing, subject to an agreed upon customer acceptance period.The following table presents a summary of the Company’s sales by revenue recognition method as a percentage of total net sales for the three months ended March 31:
| % of Total Net Sales | ||||
2023 |
| 2022 |
| ||
Point-in-Time |
| 100 | % | 100 | % |
Remaining Performance Obligations
As of March 31, 2023, the Company had approximately $165,000 of remaining performance obligations under a current waveguide development project, which represents the remainder of the total transaction price of approximately $800,000 under this development agreement, which commenced in 2022, less revenue recognized under percentage of completion to date. The Company expects to recognize the remaining revenue related to this project in the second quarter of 2023. Revenues earned less amounts invoiced at March 31, 2023 in the amount of $192,177 are reflected as Accrued Revenues in Excess of Billings in the accompanying Consolidated Balance Sheet.
The Company had no material outstanding performance obligations related to product sales, other than its standard product warranty.
Note 3 – Loss Per Share
Basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution from the assumed exercise of stock options. During periods of net loss, all common stock equivalents are excluded from the diluted EPS calculation because they are anti-dilutive. Since the Company reported a net loss for the three months ended March 31, 2023 and 2022, the calculation for basic and diluted earnings per share is considered to be the same, as the impact of potential common shares is anti-dilutive. At March 31, 2023 and 2022, there were 8,603,308 and 8,611,365 common stock share equivalents, respectively, potentially exercisable or issuable under conversion or exercise of stock options that could dilute basic earnings per share in the future.
Note 4 – Inventories, Net
Inventories are stated at the lower of cost and net realizable value, and consisted of the following:
March 31, | December 31, | |||||
| 2023 |
| 2022 | |||
Purchased Parts and Components | $ | 10,018,357 | $ | 10,399,527 | ||
Work-in-Process |
| 358,857 |
| 344,242 | ||
Finished Goods |
| 2,255,516 |
| 1,941,689 | ||
Less: Reserve for Obsolescence |
| (1,771,051) |
| (1,417,489) | ||
Inventories, Net | $ | 10,861,679 | $ | 11,267,969 |
9
Note 5 – Fixed Assets
Fixed Assets consisted of the following:
March 31, | December 31, | |||||
| 2023 |
| 2022 | |||
Tooling and Manufacturing Equipment | $ | 8,050,657 | $ | 6,065,445 | ||
Leaseholds |
| 1,366,128 |
| 826,329 | ||
Computers and Purchased Software |
| 765,237 |
| 760,256 | ||
Furniture and Equipment |
| 2,505,091 |
| 2,487,650 | ||
| 12,687,113 |
| 10,139,680 | |||
Less: Accumulated Depreciation |
| (6,547,174) |
| (6,261,175) | ||
Fixed Assets, Net | $ | 6,139,939 | $ | 3,878,505 |
During the three months ended March 31, 2023, the Company invested approximately $2,200,000 in tooling and manufacturing equipment and leasehold improvements, as part of the Company’s new waveguide expansion project. Construction on the Company’s new facility began late in December 2022 and is expected to be completed by the end of May 2023.
Total depreciation expense for fixed assets, not included in Cost of Sales, for the three months ended March 31, 2023 and 2022 was $102,451 and $117,087, respectively.
Note 6 – Technology Licenses, Net
March 31, | December 31, | |||||
| 2023 |
| 2022 | |||
Licenses | $ | 32,443,356 | $ | 2,443,356 | ||
Additions |
| — |
| 30,000,000 | ||
Less: Accumulated Amortization |
| (3,111,551) |
| (2,284,667) | ||
Licenses, Net | $ | 29,331,805 | $ | 30,158,689 |
Total amortization expense related to technology licenses for the three months ended March 31, 2023 and 2022 was $826,884 and $56,700, respectively.
Note 7 - Other Assets
March 31, | December 31, | |||||
| 2023 |
| 2022 | |||
Private Corporation Investments | $ | 450,000 | $ | 450,000 | ||
Additions | 100,000 | — | ||||
Total Private Corporation Investments (at cost) | 550,000 | 450,000 | ||||
Software Development Costs | 875,000 | 750,000 | ||||
Additions | 125,000 | 125,000 | ||||
Less: Accumulated Amortization | (430,556) | (375,000) | ||||
Software Development Costs, Net | 569,444 | 500,000 | ||||
Unamortized Common Stock Expense included in Long-Term Prepaid Expenses | 596,552 | 631,143 | ||||
Total Other Assets | $ | 1,715,996 | $ | 1,581,143 |
10
In 2021, the Company acquired, for a purchase price of $200,000, an ownership interest of 3%, in the form of preferred stock, in a private corporation developing smart glasses software for use by retailers in the stock keeping of inventory, amongst other uses. In the three months ended March 31, 2023, the Company purchased an additional $100,000 of preferred stock in this corporation through a subsequent round of funding in order to retain 2% ownership interest.
During 2020, the Company invested $500,000 in Android operating systems upgrades for its CPU platform used in its M400 and M4000 products. This upgrade was finished and placed into service in the beginning of the fourth quarter of 2020. This capitalized asset is being amortized on a straight-line basis over its expected product life cycle of
(36) months, which began on October 1, 2020. In October 2021, the Company invested $250,000 and in the first quarter of 2022 the Company invested an additional $125,000 for further Android operating systems version upgrades to the CPU platform it uses in its M400 and M4000 products. In the three months ended March 31, 2023, a final investment of $125,000 was made to these system upgrades, which were placed into service during the quarter. These additional upgrades of $500,000 are being amortized on a straight-line base over ( ) months.Total amortization expense related to all software updates for the three months ended March 31, 2023 and 2022 were $55,556 and $41,666, respectively.
Note 8 – Accrued Expenses
Accrued expenses consisted of the following:
March 31, | December 31, | |||||
| 2023 |
| 2022 | |||
Accrued Wages and Related Costs | $ | 580,002 | $ | 843,537 | ||
Accrued Professional Services |
| 189,760 |
| 263,800 | ||
Accrued Warranty Obligations |
| 194,427 |
| 159,927 | ||
Other Accrued Expenses |
| 502,025 |
| 403,275 | ||
Total | $ | 1,466,214 | $ | 1,670,539 |
The Company has warranty obligations in connection with the sale of certain of its products. The warranty period for its products is generally
(12) months. The costs incurred to provide for these warranty obligations are estimated and recorded as an accrued expense at the time of sale. The Company estimates its future warranty costs based upon product-based historical performance rates and related costs to repair. Included in Other Accrued Expenses is $435,000 for external development work related to our waveguide development projects which was completed through March 31, 2023 but not yet invoiced.The changes in the Company’s accrued warranty obligations for the three months ended March 31, 2023 were as follows:
Accrued Warranty Obligations at December 31, 2022 | $ | 159,927 | |
Reductions for Settling Warranties |
| (91,241) | |
Warranties Issued During Year |
| 125,741 | |
Accrued Warranty Obligations at March 31, 2023 | $ | 194,427 |
Note 9 – Income Taxes
The Company’s effective income tax rate is a combination of federal, state and foreign tax rates and differs from the U.S. statutory rate due to taxes on foreign income, permanent differences including tax-exempt interest, and the resolution of tax uncertainties, offset by a valuation allowance against U.S. deferred income tax assets.
11
Note 10 – Capital Stock
Preferred stock
The Board of Directors is authorized to establish and designate different series of preferred stock and to fix and determine their voting powers and other rights and terms. A total of 5,000,000 shares of preferred stock with a par value of $0.001 are authorized as of March 31, 2023 and December 31, 2022. Of this total, 49,626 shares are designated as Series A Preferred Stock. There were nil shares of Series A Preferred Stock issued and outstanding on March 31, 2023 and December 31, 2022, respectively.
Common Stock
The Company’s authorized common stock consists of 100,000,000 shares, par value of $0.001. There were 63,787,858 shares issued and 63,208,186 shares outstanding as of March 31, 2023 and 63,783,779 shares issued and 63,319,107 shares outstanding as of December 31, 2022.
Treasury Stock
On March 2, 2022, our Board of Directors approved the repurchase by the Company of up to an aggregate of $25 million of our common stock by open market or privately negotiated transactions under the Share Buyback Program. This program was in effect for one year and expired on March 2, 2023. During the three months ended March 31, 2023, the Company repurchased 115,000 shares of our common stock at an average cost of $4.06, before commission of $0.03 per share. As of March 31, 2023, 579,672 shares of our common stock were held in treasury.
Note 11 – Stock-Based Compensation
A summary of stock option activity related to the Company’s standard employee incentive plan (excluding options awarded under the Long-Term Incentive Plan (LTIP) – Note 12) for the three months ended March 31, 2023 is as follows:
Weighted | Average | ||||||
Number of | Average | Remaining Life | |||||
| Options |
| Exercise Price |
| (years) | ||
Outstanding at December 31, 2022 |
| 2,805,673 | $ | 7.80 |
| 7.28 | |
Granted |
| 25,000 |
| 3.64 |
|
| |
Exercised |
| (2,512) |
| 1.33 |
|
| |
Expired or Forfeited |
| (8,853) |
| 15.23 |
|
| |
Outstanding at March 31, 2023 |
| 2,819,308 | $ | 7.74 |
| 7.07 |
The weighted average remaining contractual term for all options as of March 31, 2023 and December 31, 2022 was 7.07 years and 7.28 years, respectively.
As of March 31, 2023, there were 1,642,429 options that were fully-vested and exercisable at a weighted average exercise price of $6.94 per share. The weighted average remaining contractual term of the vested options is 6.2 years.
As of March 31, 2023, there were 1,176,879 unvested options exercisable at a weighted average exercise price of $8.84 per share. The weighted average remaining contractual term of the unvested options is 8.3 years.
The weighted average fair value of option grants was calculated using the Black-Scholes-Merton option pricing method. As of March 31, 2023, the Company had $7,393,432 of unrecognized stock compensation expense, which will be recognized over a weighted average period of 2.3 years.
12
For the three months ended March 31, 2023 and 2022, the Company recorded total stock-based compensation expense, including stock awards but excluding awards under the Company’s LTIP, of $1,129,566 and $1,350,610, respectively.
Note 12 – Long-Term Incentive Plan
On March 17, 2021, the Company granted options to purchase a total of 5,784,000 shares of common stock to its officers and certain other members of its management team. The options were granted under the Company’s existing 2014 Incentive Stock Plan. The options have an exercise price of $19.00, with 375,000 options vesting immediately and the remaining portion vesting upon the achievement of certain equity market capitalization milestones, and revenue and EBITDA operational milestones. For the three months ended March 31, 2023 and 2022, the Company recorded non-cash stock-based compensation expense of $2,537,944 and $2,969,138, respectively, for options that vested or are probable to vest. These expenses are presented in the same financial statement line items in the Statements of Operations as the cash-based compensation expenses for the same employees.
The fair value of option grants was calculated using a Monte Carlo simulation for the equity market capitalization tranches and the Black-Scholes-Merton option pricing method for the operational milestone tranches. As of March 31, 2023, we had $14,671,988 of total unrecognized stock-based compensation expense for the portion of options tied to equity market capitalization milestones and the portion of options tied to operational milestones that were considered probable of achievement, all of which will be recognized over a service period of up to
to four years. The probabilities of the milestone achievements are subject to catch-up adjustments in each instance where an equity market capitalization milestone is achieved or when an operational milestone becomes probable to be achieved or is achieved. Compensation costs could be reversed in subsequent periods if an awardee leaves the Company prior to the expiration of the option life for market capitalization milestone or performance award vesting of a performance award no longer determined to be probable. If such milestones are achieved earlier in their expected service periods, the remaining unrecognized compensation expense related to that particular milestone would be accelerated and recognized in full during the period where that achievement is affirmed by the Board of Directors. As of December 31, 2022, and going forward, should all of the operational milestones which are currently not yet deemed probable of achievement become probable of achievement or are achieved, then the Company could ultimately recognize up to an additional $34.1 million in non-cash stock-based compensation expense at such time.The unvested remaining equity market and operational milestones under the LTIP with their total related option grants and criteria achievement weightings of the options available for meeting a target are shown in the following table. Of the total 5,409,000 unvested options outstanding as of March 31, 2023, there are 2,704,500 options unvested for the achievement of Equity Market Capitalization targets, 1,893,150 unvested options for the achievement of annual Revenue targets, and 811,350 unvested options for the achievement of annual EBITDA Margins Before Non-Cash Charges targets.
Award Potential | Criteria Achievement Weighting | ||
50% of Options Available | 35% of Options Available | 15% of Options Available | |
Options Available | Equity Market | Last Twelve Months Revenue | Last Twelve Months EBITDA |
686,000 | $ 2,000,000,000 | $ 25,000,000 | 0.0% |
686,000 | 3,000,000,000 | 50,000,000 | 2.0% |
686,000 | 4,000,000,000 | 100,000,000 | 4.0% |
686,000 | 5,000,000,000 | 200,000,000 | 6.0% |
586,000 | 6,000,000,000 | 300,000,000 | 8.0% |
586,000 | 7,000,000,000 | 450,000,000 | 10.0% |
561,000 | 8,000,000,000 | 675,000,000 | 12.0% |
491,000 | 9,000,000,000 | 1,000,000,000 | 14.0% |
441,000 | 10,000,000,000 | 1,500,000,000 | 16.0% |
5,409,000 |
13
Note 13 – Litigation
We are not currently involved in any actual or pending legal proceedings or litigation that we consider to be material, and we are not aware of any such material proceedings contemplated by or against us or involving our property.
Note 14 – Right-of-Use Assets and Liabilities
Future lease payments under operating leases as of March 31, 2023 were as follows:
2023 | $ | 523,238 | |
2024 |
| 191,120 | |
2025 |
| 132,982 | |
Total Future Lease Payments |
| 847,340 | |
Less: Imputed Interest |
| (55,736) | |
Total Lease Liability Balance | $ | 791,604 |
Operating lease costs under the operating leases totaled $203,339 and $162,365 for the three months ended March 31, 2023 and 2022, respectively.
As of March 31, 2023, the weighted average discount rate was 7.1% and the weighted average remaining lease term was 1.7 years.
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of financial condition and results of operations in conjunction with the financial statements and related notes appearing elsewhere in this quarterly report and in our Annual Report on Form 10-K for the year ended December 31, 2022.
As used in this report, unless otherwise indicated, the terms “Company,” “Vuzix”, “management,” “we,” “our,” and “us” refer to Vuzix Corporation.
Critical Accounting Policies and Significant Developments and Estimates
The discussion and analysis of our financial condition and results of operations is based upon our unaudited consolidated financial statements and related notes appearing elsewhere in this quarterly report. The preparation of these statements in conformity with GAAP requires the appropriate application of certain accounting policies, many of which require us to make estimates and assumptions about future events and their impact on amounts reported in our consolidated financial statements, including the statement of operations, balance sheet, cash flow and related notes. We continually evaluate our estimates used in the preparation of our financial statements, including those related to revenue recognition, bad debts, inventories, warranty reserves, product warranty, carrying value of long-lived assets, fair value measurement of financial instruments, valuation of stock compensation awards, achievement of equity market capitalization and probability of operational milestones being achieved under our LTIP, and income taxes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not apparent from other sources. Since future events and their impact cannot be determined with certainty, the actual results will inevitably differ from our estimates. Such differences could be material to the consolidated financial statements.
We believe that our application of accounting policies, and the estimates inherently required therein, are reasonable. We periodically re-evaluate these accounting policies and estimates and make adjustments when facts and circumstances dictate a change. Historically, we have found our application of accounting policies to be appropriate, and actual results have not differed materially from those determined using such necessary estimates.
14
Management believes certain factors and trends are important in understanding our financial performance. The critical accounting policies, judgments and estimates that we believe have the most significant effect on our consolidated financial statements are:
● | Valuation of inventories; |
● | Variable Interest Entities; |
● | Business combinations; |
● | Carrying value of long-lived assets; |
● | Software development costs; |
● | Revenue recognition; |
● | Product warranty; |
● | Stock-based compensation; and |
● | Income taxes. |
Our accounting policies are more fully described in the notes to our consolidated financial statements included in this quarterly report and in our Annual Report on Form 10-K for the year ended December 31, 2022. There have been no significant changes in our accounting policies for the three months ended March 31, 2023.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have, or are reasonably likely to have, an effect on our financial condition, financial statements, revenues or expenses.
Business Matters
We are engaged in the design, manufacture, marketing and sale of wearable computing devices and augmented reality wearable display devices, also referred to as head mounted displays (or HMDs), heads-up displays (HUDs) or near-eye displays, in the form of Smart Glasses and Augmented Reality (AR) glasses. Our wearable display devices are worn like eyeglasses or attach to a head-worn mount. These devices typically include cameras, sensors, and a computer that enable the user to view, record and interact with video and digital content, such as computer data, the internet, social media or entertainment applications. Our wearable display products integrate display technology with our advanced optics to produce compact high-resolution display engines, less than half an inch diagonally, which when viewed through our Smart Glasses products create virtual images that appear comparable in size to that of a computer monitor or a large-screen television.
With respect to our Smart Glasses and AR products, we are focused on the enterprise, industrial, commercial, security, first responder, medical, and defense markets. We also provide custom solutions and engineering services to third parties, including OEMs, of waveguides to enable fully-integrated wearable display systems, including HMDs to commercial, industrial and defense customers. We do not offer “work-for-hire” services per se but rather offer our engineering services for projects that we expect could result in advancing our technology and potentially lead to long-term supply or OEM relationships.
All of the mobile displays and wearable and mobile electronics markets in which we compete, including mobile and wearable displays and electronics, have been and continue to be subject to consistent and rapid technological change, with ever greater capabilities and performance, including mobile devices with larger screen sizes and improved display resolutions as well as, in many cases, reductions in pricing for mobile devices. As a result, we must continue to
15
improve our products’ performance and lower our costs. We believe our intellectual property portfolio gives us a leadership position in the design and manufacturing of micro-display projection engines, waveguides, mechanical packaging, ergonomics, and optical systems.
Recent Accounting Pronouncements
See Note 1 to the Unaudited Consolidated Financial Statements.
Results of Operations
Comparison of Three Months Ended March 31, 2023 and 2022
The following table compares the Company’s consolidated statements of operations data for the three months ended March 31, 2023 and 2022:
Three Months Ended March 31, |
| |||||||||||
|
|
| Dollar |
| % Increase |
| ||||||
2023 | 2022 | Change | (Decrease) |
| ||||||||
Sales: |
|
|
|
|
|
|
|
| ||||
Sales of Products | $ | 4,191,361 |
| $ | 2,503,051 |
| $ | 1,688,310 |
| 67 | % | |
|
|
|
|
|
|
|
| |||||
Cost of Sales: |
|
|
|
|
|
|
|
| ||||
Cost of Sales - Products |
| 3,082,439 |
| 1,803,598 |
| 1,278,841 |
| 71 | % | |||
Cost of Sales - Depreciation and Amortization |
| 232,916 |
| 223,785 |
| 9,131 |
| 4 | % | |||
|
|
|
|
|
|
|
| |||||
Total Cost of Sales |
| 3,315,355 |
| 2,027,383 |
| 1,287,972 |
| 64 | % | |||
|
|
|
|
|
|
|
| |||||
Gross Profit |
| 876,006 |
| 475,668 |
| 400,338 |
| 84 | % | |||
Gross Profit % |
| 21 | % | 19 | % |
|
|
| ||||
|
|
|
|
|
|
|
| |||||
Operating Expenses: |
|
|
|
|
|
|
|
| ||||
Research and Development |
| 3,069,797 |
| 3,103,444 |
| (33,647) |
| (1) | % | |||
Selling and Marketing |
| 2,539,659 |
| 2,023,435 |
| 516,224 |
| 26 | % | |||
General and Administrative |
| 5,131,824 |
| 5,453,833 |
| (322,009) |
| (6) | % | |||
Depreciation and Amortization |
| 964,265 |
| 259,245 |
| 705,020 |
| 272 | % | |||
Impairment of Patents and Trademarks |
| 17,666 |
| 49,603 |
| (31,937) |
| (64) | % | |||
|
|
|
|
|
|
|
| |||||
Loss from Operations |
| (10,847,205) |
| (10,413,892) |
| (433,313) |
| 4 | % | |||
|
|
|
|
|
|
| ||||||
Other Income (Expense): |
|
|
|
|
|
|
|
| ||||
Investment Income |
| 695,783 |
| 6,280 |
| 689,503 |
| 10,979 | % | |||
Income and Other Taxes |
| (87,795) |
| (47,632) |
| (40,163) |
| 84 | % | |||
Foreign Exchange Loss |
| (1,366) |
| (50,757) |
| 49,391 |
| (97) | % | |||
|
|
|
|
|
|
|
| |||||
Total Other Income (Expense), Net |
| 606,622 |
| (92,109) |
| 698,731 |
| (759) | % | |||
|
|
|
|
|
|
|
| |||||
Loss Before Provision for Income Taxes |
| (10,240,583) |
| (10,506,001) |
| 265,418 |
| (3) | % | |||
Provision for Income Taxes |
| — |
| — |
| — |
| — | % | |||
|
|
|
|
|
|
|
| |||||
Net Loss | $ | (10,240,583) | $ | (10,506,001) | $ | 265,418 |
| (3) | % |
16
Sales. There was an increase in total sales for the three months ended March 31, 2023 compared to the same period in 2022 of $1,688,310, or 67%. The following table reflects the major components of our sales:
| Three Months Ended | % of | Three Months Ended | % of | Dollar | % Increase |
| |||||||||
March 31, 2023 | Total Sales | March 31, 2022 | Total Sales | Change | (Decrease) | |||||||||||
Sales of Products | $ | 4,191,361 |
| 100 | % | 2,503,051 |
| 100 | % | $ | 1,688,310 |
| 67 | % |
Sales of products increased by 67% for the three months ended March 31, 2023 compared to the same period in 2022. Smart glasses revenue was the primary driver of this increase, as unit sales of our M400 product increased significantly, partially offset by higher average sales discounts due to larger volume reseller sales, as compared to that during the same period in 2022.
There were no engineering services revenue for the three months ended March 31, 2023 and 2022.
Cost of Sales and Gross Profit. Cost of product revenues and engineering services are comprised of materials, components, labor, warranty costs, freight costs, manufacturing overhead, software royalties, the non-cash depreciation for our tooling and manufacturing equipment, and amortization of software development costs related to the production of our products and rendering of engineering services. The following table reflects the components of our cost of goods sold:
Three Months Ended | As % Related | Three Months Ended | As % Related | Dollar | % Increase | |||||||||||
March 31, 2023 | Total Sales | March 31, 2022 | Total Sales | Change | (Decrease) | |||||||||||
Product Cost of Sales |
| 2,546,951 |
| 61 | % | $ | 1,406,745 |
| 56 | % | $ | 1,140,206 |
| 81 | % | |
Manufacturing Overhead - Unapplied |
| 535,488 |
| 13 | % | 396,853 |
| 16 | % | 138,635 |
| 35 | % | |||
Depreciation and Amortization | 232,916 | 6 | % | 223,785 | 9 | % | 9,131 | 4 | % | |||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||
Total Cost of Sales | $ | 3,315,355 |
| 79 | % | $ | 2,027,383 |
| 81 | % | $ | 1,287,972 |
| 64 | % | |
|
|
|
|
|
|
|
|
|
|
|
| |||||
Gross Profit | $ | 876,006 |
| 21 | % | $ | 475,668 |
| 19 | % | $ | 400,338 |
| 84 | % |
For the three months ended March 31, 2023, gross profit from total sales was $876,006 or 21% as compared to $475,668 or 19% in the same period in 2022.
Manufacturing overhead costs, not already added in Cost of Sales, increased by $138,635 or 35% for the three months ended March 31, 2023 over the 2022 comparable period, however, such costs decreased as a percentage of total sales to 13% as compared to 16% in 2022. The increase in the net dollar amount of these unapplied overhead costs in the current period versus the prior period was primarily driven by lower than planned production output due to some supply chain issues, which have improved significantly in the second quarter.
17
Research and Development. Our research and development expenses consist primarily of compensation costs for personnel, including non-cash stock-based compensation expenses, third-party services, purchase of research supplies and materials, and consulting fees related to research and development. Software development expenses to determine technical feasibility before final development and ongoing maintenance are not capitalized and are included in research and development expenses.
Three Months Ended | % of | Three Months Ended | % of | Dollar | % Increase | |||||||||||
March 31, 2023 | Total Sales | March 31, 2022 | Total Sales | Change | (Decrease) | |||||||||||
Research and Development | $ | 3,069,797 |
| 73 | % | $ | 3,103,444 |
| 124 | % | $ | (33,647) |
| (1) | % |
Research and development expenses for the three months ended March 31, 2023 decreased by $33,647 or 1%, as compared to the same period in 2022. This decrease was largely due to a decline of $61,300 in recruitment and hiring expenses, mostly offset by an increase of $52,243 in external development expenses and consultants related to our new products.
Selling and Marketing. Selling and marketing expenses consist of trade show costs, advertising, sales samples, travel costs, sales staff compensation costs including non-cash stock-based compensation expense, consulting fees, public relations agency fees, website costs and sales commissions paid to full-time staff and outside consultants.
Three Months Ended | % of | Three Months Ended | % of | Dollar | % Increase | |||||||||||
| March 31, 2023 |
| Total Sales | March 31, 2022 |
| Total Sales | Change |
| (Decrease) | |||||||
Selling and Marketing | $ | 2,539,659 | 61 | % | $ | 2,023,435 | 81 | % | $ | 516,224 | 26 | % |
Selling and marketing expenses for the three months ended March 31, 2023 increased by $516,224 or 26%, as compared to the same period in 2022. This increase was largely due to a $541,848 increase in salary and salary benefits related expenses, driven by headcount increase; and an increase of $92,193 in travel related expenses; partially offset by a decrease of $52,780 in commissions; a decrease of $33,544 in advertising and tradeshow expenses; a decrease of $31,363 in website development and maintenance costs; and a decrease of $27,763 in sales consulting fees.
General and Administrative. General and administrative expenses include professional fees, investor relations (IR) costs, salaries and related non-cash stock-based compensation, travel costs, office and rental costs.
Three Months Ended | % of | Three Months Ended | % of | Dollar | % Increase | |||||||||||
March 31, 2023 | Total Sales | March 31, 2022 | Total Sales | Change | (Decrease) | |||||||||||
General and Administrative | $ | 5,131,824 |
| 122 | % | $ | 5,453,833 |
| 218 | % | $ | (322,009) |
| (6) | % |
General and administrative expenses for the three months ended March 31, 2023 decreased by $322,009 or 6%, as compared to the same period in 2022. This decrease was largely due to a decrease of $562,119 in salary and salary benefits related expenses, which was primarily driven by a decrease in non-cash stock-based compensation related to the Company’s LTIP; a decrease of $64,617 in accounting and tax services expenses; and a $37,082 decrease in legal expenses; partially offset by an increase of $198,767 in shareholder and IR related expenses; a $84,575 increase in consulting fees; and a $36,647 increase in insurance premiums.
Depreciation and Amortization. Depreciation and amortization expense, not included in Cost of Sales, for the three months ended March 31, 2023 was $964,265, as compared to $259,245 in the same period in 2022, an increase of $705,020 The increase in depreciation and amortization expense is primarily due to the amortization of our technology license related to the Atomistic Agreements, which began on May 12, 2022.
18
Other Income (Expense), Net. Total other income was $606,622 for the three months ended March 31, 2023, as compared to other expense of $92,109 in the same period in 2022, an increase of $698,731. The overall increase in other income was primarily the result of an increase of $689,503 in investment income resulting from the recent rise in interest rates earned on the Company’s excess cash period over period; and a decrease in foreign exchange losses of $49,391; partially offset by an increase of $40,163 in income and other taxes.
Provision for Income Taxes. There was not a provision for income taxes in the respective three month periods ending March 31, 2023 and 2022.
Liquidity and Capital Resources
Capital Resources: As of March 31, 2023, we had cash and cash equivalents of $63,235,863, a decrease of $9,328,080 from $72,563,943 as of December 31, 2022.
As of March 31, 2023, we had current assets of $79,910,801 as compared to current liabilities of $12,864,249 which resulted in a positive working capital position of $67,046,552. As of December 31, 2022, we had a working capital position of $75,963,883. Our current liabilities are comprised principally of accounts payable, accrued expenses, licensing fee commitments, and operating lease right-of-use liabilities.
Summary of Cash Flow:
The following table summarizes our select cash flows for the three months ended:
March 31, | March 31, | |||||
| 2023 |
| 2022 | |||
Net Cash Provided by (used in) |
|
|
|
| ||
Operating Activities | $ | (4,164,727) | $ (6,435,079) | |||
Investing Activities |
| (4,692,596) |
| (217,227) | ||
Financing Activities |
| (470,757) |
| (221,833) |
During the three months ended March 31, 2023, we used $4,164,727 of cash for operating activities. Net changes in working capital items were $1,193,500 for the three months ended March 31, 2023, with the largest factors resulting from a $930,926 decrease in inventory and vendor prepayments; and a $218,520 decrease in other prepaid expenses. For the three months ended March 31, 2022, we used a total of $6,435,079 in cash for operating activities.
During the three months ended March 31, 2023, we used $4,692,596 of cash for investing activities, which included $2,000,000 in payments made towards our technology license fee commitment, $2,284,968 for purchases of manufacturing equipment and leasehold improvement expenditures related to our waveguide expansion project; $182,628 in patent and trademark expenditures; a further investment of $125,000 in the purchase of software operating license upgrades for our smart glasses platform; and an additional $100,000 investment in a private corporation as discussed in Note 7. For the three months ended March 31, 2022, we used a total of $217,227 in cash for investing activities.
During the three months ending March 31, 2023, we used $470,757 in net cash for financing activities, which was for share repurchases under our Share Buyback Program that was announced on March 2, 2022 and expired on March 2, 2023. For the three months ended March 31, 2022, we used $221,833 in net cash for financing activities.
As of March 31, 2023, the Company does not have any current or long-term debt obligations outstanding other than licensing fee commitments totaling $9,500,000, which are all current.
19
The Company’s cash requirements are primarily for funding operating losses, working capital, research and development, capital expenditures, and licensing fee commitments. We incurred a net loss for the three months ended March 31, 2023 of $10,240,583 (of which $3,667,509 was related to non-cash stock-based compensation primarily due to our LTIP) and for the years ended December 31, 2022 and 2021 of $40,763,573 (of which $15,775,553 was related to non-cash stock-based compensation primarily due to our LTIP) and $40,377,160 (of which $17,302,833 was related to non-cash stock-based compensation primarily due to our LTIP), respectively. The Company has an accumulated deficit of $254,076,299 as of March 31, 2023.
On March 2, 2022, our Board of Directors approved the repurchase by the Company of up to an aggregate of $25 million of our common stock by open market or privately negotiated transactions under the Share Buyback Program. This program was in effect for one year, did not obligate the Company to acquire any particular amount of common stock, and could have been suspended or discontinued at any time at the Company’s sole discretion. During the three months ended March 31, 2023, the Company repurchased 115,000 shares of our common stock at an average cost of $4.06, before commission of $0.03 per share. As of March 31, 2023, 579,672 shares of our common stock were held in treasury.
Our operations have historically been financed primarily through net proceeds from the sale of our equity securities. As of March 31, 2023, our principal sources of liquidity consisted of cash and cash equivalents of $63,235,863.
Forward Looking Statements
This quarterly report includes forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements include, but are not limited to, statements concerning:
● | trends in our operating expenses, including personnel costs, research and development expense, sales and marketing expense, and general and administrative expense; |
● | the effect of competitors and competition in our markets; |
● | our wearable smart glasses products and their market acceptance and future potential; |
● | our ability to develop, timely introduce, and effectively manage the introduction of new products and services or improve our existing products and services; |
● | expected technological advances by us or by third parties and our ability to leverage them; |
● | our ability to attract and retain customers; |
● | our ability to accurately forecast consumer demand and adequately manage our inventory; |
● | our ability to deliver an adequate supply of product to meet demand; |
● | our ability to maintain and promote our brand and expand brand awareness; |
● | our ability to detect, prevent, or fix defects in our products; |
● | our reliance on third-party suppliers, contract manufacturers and logistics providers and our limited control over such parties; |
● | trends in revenue, costs of revenue, and gross margin and our possible or assumed future results of operations; |
20
● | our ability to attract and retain highly skilled employees; |
● | the impact of foreign currency exchange rates; |
● | the effect of future regulations; |
● | the sufficiency of our existing cash and cash equivalent balances and cash flow from operations to meet our working capital and capital expenditure needs for at least the next twelve (12) months; and |
● | general market, political, economic, business and public health conditions. |
All statements in this quarterly report that are not historical facts are forward-looking statements. We may, in some cases, use terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions that convey uncertainty of future events or outcomes to identify forward-looking statements.
All such forward-looking statements are subject to certain risks and uncertainties and should be evaluated in light of important risk factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These risk factors include, but are not limited to, those that are described in “Risk Factors” in this report and under Item 1A and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2022 and other filings we make with the Securities and Exchange Commission and the following: business and economic conditions, rapid technological changes accompanied by frequent new product introductions, competitive pressures, dependence on key customers, inability to gauge order flows from customers, fluctuations in quarterly and annual results, the reliance on a limited number of third-party suppliers, limitations of our manufacturing capacity and arrangements, the protection of our proprietary technology, the effects of pending or threatened litigation, the dependence on key personnel, changes in critical accounting estimates, potential impairments related to investments, foreign regulations, liquidity issues, and potential material weaknesses in internal control over financial reporting. Further, during weak or uncertain economic periods, customers may delay the placement of their orders. These factors often result in a substantial portion of our revenue being derived from orders placed within a quarter and shipped in the final month of the same quarter.
We caution readers to carefully consider such factors. Many of these factors are beyond our control. In addition, any forward-looking statements represent our estimates only as of the date they are made and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, except as may be required under applicable securities laws, we specifically disclaim any obligation to do so.
Item 3.Quantitative and Qualitative Disclosures about Market Risk
We invest our excess cash in high-quality short-term corporate debt instruments, which bear lower levels of relative risk. We believe that the effect, if any, of possible near-term changes in interest rates on our financial position, results of operations, and cash flows should not be material to our cash flows or income. It is possible that interest rate movements would increase our unrealized gain or loss on interest rate securities. We are exposed to changes in foreign currency exchange rates primarily through transaction gains and losses as a result of non-U.S. dollar denominated cash flows related to business activities in Japan and Europe. We do not currently hedge our foreign currency exchange rate risk. We estimate that any market risk associated with our international operations is unlikely to have a material adverse effect on our business, financial condition or results of operation.
Item 4.Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Management, with the participation of the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), has performed an evaluation of the effectiveness of our disclosure controls and procedures that are defined in
21
Rule 13a-15 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of the end of the period covered by this report. This evaluation included consideration of the controls, processes, and procedures that are designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is properly recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our management, including our CEO and CFO, concluded that our disclosure controls and procedures were effective at March 31, 2023.
Changes in Internal Control over Financial Reporting
There have not been any changes in the Company’s internal control over financial reporting (as defined in 13a-15(f) and 15d-15(f) promulgated under the Exchange Act) that occurred during the Company’s most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
Part II. OTHER INFORMATION
Item 1.Legal Proceedings
We are not currently involved in any actual or pending legal proceedings or litigation that we consider to be material, and we are not aware of any such proceedings contemplated by or against us or involving our property.
Item 1A.Risk Factors
In addition to the other information set forth in this report you should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022. There have been no material changes from those risk factors. The risks discussed in our 2022 Annual Report could materially affect our business, financial condition and future results.
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds
Sale of Unregistered Securities – none
Purchase of Equity Securities:
Period |
| Total number |
| Average |
| Total number |
| Maximum dollar value | ||
January 3, 2023 – January 18. 2023 | 115,000 | $ | 4.06 | 579,672 | $ | - |
(1) | On March 2, 2022, our Board of Directors approved the repurchase by the Company of up to an aggregate of $25 million of our common stock by open market or privately negotiated transactions under the Share Buyback Program. An aggregate amount of $2,476,501 was purchased under this program between March 2022 and January 2023. This program expired on March 2, 2023. |
Item 3.Defaults Upon Senior Securities
None
Item 4.Mine Safety Disclosures
Not Applicable
Item 5.Other Information
None
22
Item 6.Exhibits
Exhibit No. |
| Description |
| ||
31.1 | ||
|
| |
31.2 | ||
|
| |
32.1 | ||
|
| |
32.2 | ||
|
| |
101.INS | Inline XBRL Instance Document | |
|
| |
101.SCH | Inline XBRL Taxonomy Extension Schema Document | |
|
| |
101.CAL | Inline XBRL Taxonomy Extension Calculation Link base Document | |
|
| |
101.DEF | Inline XBRL Taxonomy Extension Definition Link base | |
|
| |
101.LAB | Inline XBRL Taxonomy Extension Label Link base Document | |
|
| |
101.PRE | Inline XBRL Taxonomy Extension Presentation Link base Document | |
104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)* |
* Filed herewith.
** Furnished herewith
.
23
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| VUZIX CORPORATION | |
|
|
|
Date: May 10, 2023 | By: | /s/ Paul Travers |
|
| Paul Travers |
|
| President, Chief Executive Officer |
|
| (Principal Executive Officer) |
|
|
|
Date: May 10, 2023 | By: | /s/ Grant Russell |
|
| Grant Russell |
|
| Executive Vice President and Chief Financial |
|
| Officer |
|
| (Principal Financial and Accounting Officer) |
24